Invention Grant
- Patent Title: Acylated glucagon analogue
-
Application No.: US15566338Application Date: 2016-04-15
-
Publication No.: US10336802B2Publication Date: 2019-07-02
- Inventor: Ditte Riber , Jakob Lind Tolborg , Dieter Wolfgang Hamprecht , Leo Thomas
- Applicant: Zealand Pharma A/S , Boehringer Ingelheim International GmbH
- Applicant Address: DK Glostrup
- Assignee: Zealand Pharma A/S
- Current Assignee: Zealand Pharma A/S
- Current Assignee Address: DK Glostrup
- Agency: Clark & Elbing LLP
- Priority: EP15163903 20150416
- International Application: PCT/EP2016/058359 WO 20160415
- International Announcement: WO2016/166289 WO 20161020
- Main IPC: A61K31/64
- IPC: A61K31/64 ; A61K38/22 ; A61K38/26 ; A61K38/28 ; A61K45/06 ; A61K31/135 ; A61K31/137 ; A61K31/155 ; A61K31/365 ; C07K14/605 ; A61K31/7048
Abstract:
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Public/Granted literature
- US20180094038A1 ACYLATED GLUCAGON ANALOGUE Public/Granted day:2018-04-05
Information query
